Company patents
GENMAB A/S
GENMAB A/S, despite its strong focus on core pharma_biotech categories like Peptides & Proteins (92.2% of portfolio) and Pharmaceutical Preparations (72.4%), shows a surprising and significant decline in patenting across all major categories in 2025 and so far in 2026, with Pharmaceutical Preparations dropping by 65.2% YoY in 2026 and Therapeutic Activity (Pharma) by 75.0% YoY in 2026, suggesting a potential shift in its innovation or filing strategy after a peak in 2024.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
116 US filings (since 2023) · 4 categories · 10 themes
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Methods and systems for the efficient and scalable production, purification, and formulation of proteins and peptides, including fermentation, chromatography, and cell-based expression systems.
Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Patents
Showing 1-10 of 187